Progyny, Inc. (NASDAQ:PGNY) CEO Peter Anevski Sells 32,000 Shares of Stock

Posted by Defense World Staff on May 17th, 2023

Progyny, Inc. (NASDAQ:PGNY – Get Rating) CEO Peter Anevski sold 32,000 shares of Progyny stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $36.30, for a total value of $1,161,600.00. Following the sale, the chief executive officer now directly owns 215,924 shares in the company, valued at approximately $7,838,041.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Peter Anevski also recently made the following trade(s):

On Monday, May 15th, Peter Anevski sold 32,000 shares of Progyny stock. The shares were sold at an average price of $36.24, for a total value of $1,159,680.00.
On Wednesday, May 10th, Peter Anevski sold 32,000 shares of Progyny stock. The shares were sold at an average price of $37.74, for a total value of $1,207,680.00.
On Monday, May 8th, Peter Anevski sold 22,932 shares of Progyny stock. The shares were sold at an average price of $35.09, for a total value of $804,683.88.
On Monday, April 24th, Peter Anevski sold 1,857 shares of Progyny stock. The shares were sold at an average price of $35.00, for a total value of $64,995.00.
On Friday, April 21st, Peter Anevski sold 8,370 shares of Progyny stock. The shares were sold at an average price of $35.01, for a total value of $293,033.70.
On Thursday, March 2nd, Peter Anevski sold 32,000 shares of Progyny stock. The stock was sold at an average price of $36.12, for a total value of $1,155,840.00.

Progyny Stock Performance

Progyny stock opened at $35.95 on Wednesday. The firm has a market cap of $3.39 billion, a price-to-earnings ratio of 83.60, a price-to-earnings-growth ratio of 2.13 and a beta of 1.51. Progyny, Inc. has a 1 year low of $25.67 and a 1 year high of $46.50. The firm’s 50 day moving average price is $33.34 and its two-hundred day moving average price is $33.67.

Progyny (NASDAQ:PGNY – Get Rating) last posted its quarterly earnings results on Monday, May 8th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.10. The firm had revenue of $258.40 million for the quarter, compared to analyst estimates of $246.63 million. Progyny had a net margin of 4.93% and a return on equity of 11.81%. The firm’s quarterly revenue was up 50.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.05 earnings per share. As a group, equities analysts predict that Progyny, Inc. will post 0.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Belpointe Asset Management LLC acquired a new position in Progyny in the fourth quarter worth approximately $32,000. Lazard Asset Management LLC purchased a new position in Progyny during the 1st quarter worth approximately $62,000. Parkside Financial Bank & Trust purchased a new position in Progyny during the 1st quarter worth approximately $70,000. Park Place Capital Corp grew its position in Progyny by 48.0% during the 1st quarter. Park Place Capital Corp now owns 1,424 shares of the company’s stock worth $46,000 after purchasing an additional 462 shares in the last quarter. Finally, Arcadia Investment Management Corp MI grew its position in Progyny by 130.9% during the 1st quarter. Arcadia Investment Management Corp MI now owns 1,665 shares of the company’s stock worth $53,000 after purchasing an additional 944 shares in the last quarter. Institutional investors and hedge funds own 86.12% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Bank of America boosted their target price on Progyny from $48.00 to $50.00 in a report on Tuesday, May 9th. Cantor Fitzgerald boosted their target price on Progyny from $44.00 to $45.00 in a report on Tuesday, May 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Progyny has an average rating of “Moderate Buy” and a consensus target price of $48.67.

About Progyny

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.